Rhythm Pharmaceuticals
RYTM
119 hedge funds and large institutions have $1.19B invested in Rhythm Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 37 increasing their positions, 40 reducing their positions, and 14 closing their positions.
40% more capital invested
Capital invested by funds: $851M → $1.19B (+$344M)
29% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 14
3% more funds holding
Funds holding: 115 → 119 (+4)
2.69% more ownership
Funds ownership: 88.96% → 91.65% (+2.7%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
8% less repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 40
43% less call options, than puts
Call options by funds: $3.31M | Put options by funds: $5.81M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
+$20.9M |
| 2 |
Primecap Management
Pasadena,
California
|
+$19.5M |
| 3 |
State Street
Boston,
Massachusetts
|
+$10M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$9.8M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$8.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$24.4M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.94M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$4.78M |
| 4 |
Renaissance Technologies
New York
|
-$4.75M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$3.97M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
126
Russell Investments Group
London,
United Kingdom
| – | -$127K | -5,891 | Closed |
|
|
FHA
127
Flagship Harbor Advisors
Boston,
Massachusetts
| – | -$34K | -1,572 | Closed |
|
|
NSIM
128
North Star Investment Management
Chicago,
Illinois
| – | -$7K | -300 | Closed |
|
|
S
129
SignatureFD
Atlanta,
Georgia
| – | -$4K | -200 | Closed |
|
|
PA
130
Parallel Advisors
San Francisco,
California
| – | -$2K | -90 | Closed |
|
|
GT
131
Glenmede Trust
Philadelphia,
Pennsylvania
| – | -$1K | -50 | Closed |
|
|
ABC
132
Associated Banc-Corp
Green Bay,
Wisconsin
| – | -$1K | -33 | Closed |
|
RYTM Hedge Fund Activity: Q4 2020 in Review
119 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q4 2020, worth a combined $1.19B — up 40% from $851M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new RYTM positions and 14 closed out — a net gain of 4 holders — while 37 added to existing stakes and 40 trimmed.
The largest buyer was Deerfield Management, adding an estimated $20.9M. The largest seller was RA Capital Management, cutting an estimated $24.4M.
- 119 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q4 2020, up from 115 in Q3 2020.
- Funds reported $1.19B of Rhythm Pharmaceuticals stock for Q4 2020, up 40% quarter-over-quarter.
- 18 funds opened new Rhythm Pharmaceuticals positions in Q4 2020 and 14 closed out, a net change of +4 holders.
- The largest Rhythm Pharmaceuticals buyer in Q4 2020 was Deerfield Management, an estimated $20.9M added.
- The largest Rhythm Pharmaceuticals seller in Q4 2020 was RA Capital Management, an estimated $24.4M sold.
Based on aggregated 13F filings for Q4 2020.